Larger clinical studies are necessary to evaluate the safety, efficacy, and generalizability of combining cadonilimab with disitamab vedotin in the treatment of NSCLC with HER2 amplification. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.